-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Plus Therapeutics, Lowers Price Target to $65

Benzinga·04/09/2026 10:32:17
Listen to the news
Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lowers the price target from $475 to $65.